Lutetium Lu 177-Edotreotide

also known as 177Lu-DOTATOC · 177Lu-edotreotide · 177Lu-octreotide · [177Lu]Lu-DOTATOC · Dotatoc lu-177 · Edotreotide lutetium lu-177 · Lu-177 DOTATOC · Lutecio lu177 edotreotida · +2 more

Peptide

Developed for: neuroendocrine neoplasm · paraganglioma · pheochromocytoma · breast neuroendocrine neoplasm · cancer of unknown primary site · central nervous system neoplasm · cutaneous neuroendocrine carcinoma · digestive system neuroendocrine neoplasm
+12 more
· gastrointestinal stromal tumor · lung carcinoid tumor · lung neuroendocrine neoplasm · lymphoma · ovarian neuroendocrine neoplasm · pancreatic gastrinoma · pancreatic insulinoma · peripheral primitive neuroectodermal tumor · rhabdomyosarcoma · thymic neuroendocrine tumor · VIPoma · meningioma
Investigated by: British Columbia Cancer Agency · Excel Diagnostics and Nuclear Oncology Center · ITM Solucin GmbH · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Lund University Hospital · Maria Sklodowska-Curie National Research Institute of Oncology
+7 more
· Medical University of Warsaw · National Center for Research and Development, Poland · Paul Scherrer Institute (PSI) · Swiss National Science Foundation · The Diagnostic and Therapeutic Center Gammed; Poland · University Hospital, Basel, Switzerland · University of Warmia and Mazury

Trials 7

today NCT06441331 · Ph 1 NCT06045260 · Ph 2 NCT05359146 · Ph 0 NCT04915144 · Ph 2 NCT05387603 · Ph 3 NCT04276597 · Ph 2 NCT04194125 · Ph 2

2019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05359146	Mar 2023 → Dec 2025	digestive system neuroendocrine neoplasm	University Hospital, Basel, Switzerland	Unknown	No outcome recorded
Phase 11 trial
Phase 1	NCT06441331	Sep 2025 → Jun 2028 expected	central nervous system neoplasm, gastrointestinal stromal tumor, lymphoma, neuroendocrine neoplasm +2	ITM Solucin GmbH	Recruiting	No outcome recorded
Phase 24 trials
Phase 2	NCT06045260	Sep 2023 → Feb 2025 overdue	paraganglioma, pheochromocytoma	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Recruiting	No outcome recorded
Phase 2	NCT04915144	Jan 2023 → Dec 2027	VIPoma, lung carcinoid tumor, pancreatic gastrinoma, pancreatic insulinoma	British Columbia Cancer Agency	Withdrawn	No outcome recorded
Phase 2	NCT04276597	Mar 2020 → Jul 2021	breast neuroendocrine neoplasm, cancer of unknown primary site, cutaneous neuroendocrine carcinoma, lung neuroendocrine neoplasm +4	Excel Diagnostics and Nuclear Oncology Center	Withdrawn	No outcome recorded
Phase 2	NCT04194125	Feb 2019 → Jun 2021	neuroendocrine neoplasm	University of Warmia and Mazury	Unknown	No outcome recorded
Phase 31 trial
Phase 3	NCT05387603	Nov 2022 → Oct 2026 expected	neuroendocrine neoplasm	Lund University Hospital	Recruiting	No outcome recorded
Comparator or background therapy1 trial
Phase 1/2	NCT04997317 Comparator	Apr 2021 → Dec 2026 expected	meningioma	University Hospital, Basel, Switzerland	Recruiting	No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

Field	Value	Cited text
Known as	Lutetium Lu 177-Edotreotide	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06441331 ↗
Known as	177Lu-DOTATOC	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04276597 ↗ 6 NCT04915144 ↗ NCT05359146 ↗ NCT06045260 ↗ NCT04194125 ↗ NCT04997317 ↗ NCT05387603 ↗
Known as	177Lu-edotreotide	“177Lu-DOTATOC = 177Lu-edotreotide is a therapeutic medicinal product with three main components (a) Lutetium-177 (177Lu), a beta minus and gamma--emitting radionuclide with a...” NCT05359146 ↗ 1 “"Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR Positive Patients: a Multicenter, Prospective, Phase II Trial"” NCT06045260 ↗
Known as	177Lu-octreotide	“"Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR Positive Patients: a Multicenter, Prospective, Phase II Trial"” NCT06045260 ↗
Known as	[177Lu]Lu-DOTATOC	“Our primary aim was to compare the therapeutic index (tumor-to-bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin receptor antagonist...” PMID 38423782 ↗ Apr 2024
Known as	Dotatoc lu-177	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095425 ↗
Known as	Edotreotide lutetium lu-177	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095425 ↗
Known as	Lu-177 DOTATOC	“A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin...” NCT04276597 ↗
Known as	Lutecio lu177 edotreotida	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095425 ↗
Known as	Lutecium lu177 edotreotide	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095425 ↗
Known as	Lutetium (177lu) edotreotide	ChEMBL registry synonym — accepted as the source's own label CHEMBL5095425 ↗
Action	Activate	“TOC (= \[Tyr\]3-octreotide) an agonistic somatostatin analogue which binds to sstr2 and sstr5 receptors.” NCT04997317 ↗
Modality	Peptide	“Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC” NCT04194125 ↗
Route	Intravenous	“administered i.v.” NCT04194125 ↗